BioCentury | Aug 28, 2019
Politics & Policy

Aug. 28 P&P Quick Takes: Liver failure warning for HCV drugs; plus FDA guidances and more

...glecaprevir/pibrentasvir from AbbVie Inc. (NYSE:ABBV), Zepatier grazoprevir/elbasvir from Merck & Co. Inc. (NYSE:MRK) and Vosevi sofosbuvir/velpatasvir/voxilaprevir...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...NASDAQ:BIIB) Ocrevus ocrelizumab Multiple sclerosis Australia, Israel, Switzerland, U.S., others $1,703.8 Gilead Sciences Inc. (NASDAQ:GILD) Vosevi...
BioCentury | Aug 10, 2018
Company News

Zepatier lands co-exclusive status on Express Scripts 2019 formulary

...sofosbuvir/velpatasvir, Vosevi sofosbuvir/velpatasvir/voxilaprevir and Harvoni sofosbuvir/ledipasvir, while it would exclude Mavyret glecaprevir/pibrentasvir. Gilead markets Epclusa, Vosevi...
...A 12-week treatment course of Harvoni carries a WAC of $94,500 while Epclusa and Vosevi...
BioCentury | Aug 9, 2018
Politics & Policy

China releases list of overseas drugs eligible for Priority Review

...drugs that received their first approval since the beginning of 2017 including HCV drug Vosevi sofosbuvir/velpatasvir/voxilaprevir...
BioCentury | Aug 7, 2018
Company News

Zepatier lands co-exclusive status on Express Scripts 2019 formulary

...sofosbuvir/velpatasvir, Vosevi sofosbuvir/velpatasvir/voxilaprevir and Harvoni sofosbuvir/ledipasvir, while it would exclude Mavyret glecaprevir/pibrentasvir. Gilead markets Epclusa, Vosevi...
...A 12-week treatment course of Harvoni carries a WAC of $94,500 while Epclusa and Vosevi...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Nov 3, 2017
Regulation

Frame work

...for HCV: Merck & Co. Inc.’s Zepatier elbasvir/grazoprevir; Gilead Sciences Inc.’s Epclusa sofosbuvir/velpatasvir and Vosevi sofosbuvir/velpatasvir/voxilaprevir...
...or with compensated cirrhosis, and Epclusa plus ribavirin to treat patients with decompensated cirrhosis. The Vosevi...
...were higher for Vosevi than Epclusa for genotype 1a and 3 patients, and comparable between Vosevi...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

...in patients ages two and older Gilead Sciences Inc. (NASDAQ:GILD) FDA and EC approve Vosevi sofosbuvir/velpatasvir/voxilaprevir...
BioCentury | Sep 9, 2017
Strategy

Some of the parts

...alafenamide, an HIV product with a Feb. 12, 2018, PDUFA date. The recently approved Vosevi sofosbuvir/velpatasvir/voxilaprevir...
BioCentury | Aug 4, 2017
Clinical News

European Commission approves Gilead’s HCV triple combo

...Gilead Sciences Inc. (NASDAQ:GILD) said the European Commission approved Vosevi sofosbuvir/velpatasvir/voxilaprevir to treat HCV genotypes 1-6...
...Vosevi for HCV genotypes 1-6 infection in previously treated adults (see BioCentury, July 24 ). Vosevi...
...protease inhibitor. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: Vosevi sofosbuvir/velpatasvir/ voxilaprevir Business: Infectious Alicia Parker sofosbuvir/velpatasvir/voxilaprevir Vosevi Gilead...
Items per page:
1 - 10 of 24